• Clinical outcomes in HIV care
  
  
  

• Clinical research updates
• Indications and limitations of antiretroviral therapy
• Opportunistic infection management
  
  
  

Dr Johnson is Director of the Infectious Disease Group Practice and HIV/AIDS Clinical Program at the University of Colorado Hospital in Denver. He is an Associate Professor of Medicine in the Division of Infectious Diseases, Department of Medicine at the University of Colorado Health Sciences Center.


Committees and Organizations

• Director, Infectious Disease Group Practice, University Hospital (1994-)
• Member, Committee for AIDS Drug Assistance Program Colorado (1994-)
• Member, Ryan White Planning Council Priorities Committee (1995-)
• Co-Director, Colorado AIDS Education and Training Center (1998-)
• Reviewer: AIDS Research and Human Retroviruses, Clinical Infectious Diseases, Journal Infectious Diseases, Clinical Therapeutics
  
  
  

• Elected to Fellowship, American College of Physicians (1994)
• President's Award for Outstanding Clinical Service, University of Colorado Hospital (1998)
• Infectious Disease Fellowship Teaching Award (2000)
• Denver's Top Doctors (2001)
• Best Doctors in America (2002)
  
  
  

• Bethany College, BA (1980)
• Northwestern University, MD (1984)
• Fitzsimons Army Medical Center, Residency, Internal Medicine (1984-1987)
• Walter Reed Army Medical Center, Fellowship, Infectious Diseases (1987-1990)
  
  
  

1. Teel LD, Finelli MR, Johnson SC. Isolation of Mycoplasma species from bronchoalveolar lavages of patients positive and negative for human immunodeficiency virus. J Clin Microbiol. 1994;32:1387-1389.
2. Magill AJ, Grogl M, Johnson SC, Gasser RA Jr. Visceral infection due to Leishmania tropica in a veteran of Operation Desert Storm who presented 2 years after leaving Saudi Arabia. Clin Infect Dis. 1994;19:805-806.
3. Rolfs RT, Joesoef MR, Hendershot EF, Rompalo AM, Augenbraun MH, Chiu M, Bolan G, Johnson SC, French P, Steen E, Radolf JD, Larsen S. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. N Engl J Med. 1997;337:307-314.
4. Akler ME, Johnson DW, Burman WJ, Johnson SC. Anterior uveitis and hypotony after intravenous cidofovir for the treatment of cytomegalovirus retinitis. Ophthalmology. 1998;105:651-657.
5. Young B, Johnson S, Bahktiari M, Shugarts D, Young RK, Allen M, Ramey RR 2nd, Kuritzkes DR. Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure. J Infect Dis. 1998;178:1497-1501.
6. Aronson NE, Wortmann GW, Johnson SC, Jackson JE, Gasser RA Jr, Magill AJ, Endy TP, Coyne PE, Grogl M, Benson PM, Beard JS, Tally JD, Gambel JM, Kreutzer RD, Oster CN. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. military experience. Clin Infect Dis. 1998;27:1457-1464.
7. Johnson SC, Gerber JG. Advances in HIV/AIDS therapy. Adv Intern Med. 2000;45:1-40. Review.
8. Williams WJ, Johnson SC. Syphilis. In Advances in Medicine (RF Edlich, Editor). ABI Professional Publications, Arlington, Virginia, 2000, pp. 168-172.
9. Johnson SC, Benson CA, Johnson DW, Weinberg A. Recurrences of cytomegalovirus retinitis in a human immunodeficiency virus-infected patient, despite potent antiretroviral therapy and apparent immune reconstitution. Clin Infect Dis. 2001;32:815-819.
10. Johnson SC. Syphilis. In Conn's Current Therapy, 2001 (Rakel RE and Bope ET, editors). W.B. Saunders, Philadelphia, Pennsylvania, 2001, pp. 770-772.
    
    
    
    Return to Top